United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 0.6% in the fourth quarter, Holdings Channel reports. The firm owned 100,704 shares of the biotechnology company’s stock after acquiring an additional 640 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in United Therapeutics were worth $22,144,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in UTHR. Neo Ivy Capital Management acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at about $48,000. Atlas Capital Advisors LLC acquired a new stake in shares of United Therapeutics in the 4th quarter valued at about $51,000. Northwestern Mutual Wealth Management Co. boosted its position in shares of United Therapeutics by 49.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 65 shares during the period. Zions Bancorporation N.A. acquired a new stake in shares of United Therapeutics in the 1st quarter valued at about $66,000. Finally, Quantbot Technologies LP acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at about $87,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on UTHR. The Goldman Sachs Group raised United Therapeutics from a “sell” rating to a “neutral” rating and upped their target price for the company from $213.00 to $215.00 in a research report on Monday, February 12th. Wells Fargo & Company upped their price objective on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Wedbush reaffirmed an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $294.25.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $237.93 on Monday. The company has a market cap of $11.20 billion, a price-to-earnings ratio of 11.99 and a beta of 0.52. The stock has a 50 day simple moving average of $231.71 and a 200-day simple moving average of $228.64. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $261.54. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.67 EPS. On average, equities analysts forecast that United Therapeutics Co. will post 23.45 EPS for the current year.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $215.01, for a total value of $1,290,060.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at approximately $7,869,150.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Nilda Mesa sold 325 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total value of $77,285.00. Following the completion of the transaction, the director now directly owns 5,373 shares of the company’s stock, valued at approximately $1,277,699.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $215.01, for a total value of $1,290,060.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $7,869,150.99. The disclosure for this sale can be found here. In the last three months, insiders sold 129,790 shares of company stock valued at $30,528,633. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.